.png){kind=icon}
返回
.png){kind=icon}
.png){kind=icon}
摘要
En 中文
Epcoritamab (epcoritamab-bysp; Epkinly & TRADE;; Tepkinly(& REG;)) is a subcutaneously administered CD3xCD20 T-cell-engaging bispecific antibody being co-developed by Genmab and AbbVie for the treatment of mature B-cell non-Hodgkin lymphoma subtypes (B-NHLs), including diffuse large B-cell lymphoma (DLBCL). Epcoritamab received its first (conditional) approval on 19 May 2023, in the USA, for the treatment of adult patients with relapsed or refractory (R/R) DLBCL, not otherwise specified, including DLBCL arising from indolent lymphoma, and high-grade B-cell lymphoma after & GE; 2 lines of systemic therapy. Elsewhere, epcoritamab has received a positive opinion in the EU as a monotherapy for the treatment of adults with R/R DLBCL after & GE; 2 lines of systemic therapy, and is currently under regulatory review in Japan for the treatment of adults with R/R large B-cell lymphoma after & GE; 2 lines of systemic therapy. Clinical development of epcoritamab as monotherapy and in combination with standard of care agents for the treatment of mature B-NHLs is ongoing globally. This article summarizes the milestones in the development of epcoritamab leading to this first approval for R/R DLBCL.
Keyword:
LARGE B-CELL
RITUXIMAB PLUS LENALIDOMIDE
NON-HODGKIN-LYMPHOMA
SUBCUTANEOUS EPCORITAMAB
OPEN-LABEL
TRIAL
COMBINATION
MONOTHERAPY
SAFETY
R-2
期刊
IF:
14.4
论文数:
8.4K
被引数:
2.3W
机构
暂无机构信息
引用论文
Pharmacodynamic activity of epcoritamab (GEN3013; CD3xCD20) as monotherapy is maintained in combination with standard of care therapies in patients with diffuse large B-cell lymphoma.png)
CANCER RESEARCH.png)
CANCER RESEARCHIF16.6
PREAI
.png){kind=icon}
分享.png){kind=icon}
收藏
分享收藏
查看更多内容